Post Archive by Month

As the Fall 2024 respiratory season approaches, recent studies reveal disparities in who consumers trust regarding medical information.
According to the J.D. Power 2024 U.S. Pharmacy 16th Study released today, overall satisfaction with mail-order pharmacies is rising steadily this year.
Meanwhile, chain drug stores have seen their overall satisfaction scores slide far below the brick-and-mortar category average,

While the World Health Organization (WHO) recently reported that respiratory syncytial virus (RSV) activity was not detectable in most countries, new data indicates that this respiratory virus has arrived in the United States.
According to the U.S. Centers for Disease Control and Prevention (CDC), RSV activity usually begins in Florida and then migrates to the southeast, later to the north and west regions.

The U.S. Centers for Disease Control and Prevention (CDC) announced today that it would spend $5 million to purchase influenza vaccines for farm workers to address concerns about avian influenza in dairy cows and poultry.
The CDC says avian influenza, or "bird flu," is a contagious viral disease.

The Lancet Infectious Disease recently published a Correspondence offering insights regarding the current influenza A(H5N1) outbreak in dairy cattle and poultry, raising concerns about increased risk for sustained human-to-human transmission.
On July 24, 2024, these researchers wrote that avian influenza viruses' increasing host range and ability to spread between mammals and humans raise concerns about a potential pandemic risk. This pandemic risk is a concern as mortality was 52% of the 876 influenza A(H5N1) cases reported in Europe since 2002.

Recently, there has been confusion for international travelers looking to protect themselves from dengue disease, which is transmitted to people by mosquitoes.
In January 2024, Sanofi-Pasteur announced that they would stop manufacturing the U.S. FDA-approved Dengvaxia® vaccine for children due to a lack of demand in the global market.

GSK plc and Flagship Pioneering today announced they have entered a collaboration to discover and develop a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.
This alliance combines GSK’s disease area expertise and development capability with Flagship’s ecosystem of bioplatform companies, including its novel modalities and technologies, to make significant advances in healthcare.